KERYX BIOPHARMACEUTICALS INC. news, videos and press releases
For more news please use our advanced search feature.
KERYX BIOPHARMACEUTICALS INC. - More news...
KERYX BIOPHARMACEUTICALS INC. - More news...
- INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Akebia Therapeutics, Inc. and Encourages Investors who Formerly Held Shares of Keryx Biopharmaceuticals (KERX) to Contact the Firm
- Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Keryx Biopharmaceuticals, Inc. In The U.S. District Court For The District Of Delaware
- SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Keryx Biopharmaceuticals, Inc. - KERX
- Kaskela Law LLC Announces Investigation of Keryx Biopharmaceuticals, Inc. on Behalf of Stockholders - KERX
- WeissLaw LLP Investigates Keryx Biopharmaceuticals Inc.
-
Keryx Biopharmaceuticals, Inc. - KERX Stock Chart Technical Analysis for 04-11-18
- Keryx Biopharmaceuticals, Inc. to Host Earnings Call
- Investor Network: Kimball Electronics, Inc. to Host Earnings Call
- Investor Network: Keryx Biopharmaceuticals, Inc. to Host Earnings Call
- Investor Network: Kimball Electronics, Inc. to Host Earnings Call
- SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Keryx Biopharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
-
Keryx Biopharmaceuticals
- Keryx Biopharmaceuticals Announces Publication of Auryxia® (ferric citrate) Phase 3 Trial Results for Iron Deficiency Anemia (IDA) in Non-Dialysis-Dependent Chronic Kidney Disease (NDD-CKD) in Journal of the American Society of Nephrology
- Keryx Biopharmaceuticals Announces Recent Business Progress and Reviews Corporate Strategy at 35th Annual J.P. Morgan Healthcare Conference
- Keryx Biopharmaceuticals to Webcast its Presentation at J.P. Morgan’s 35th Annual Healthcare Conference on January 11, 2017
- Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week
- Keryx Biopharmaceuticals Announces Multiple Scientific Presentations of Phase 3 Trial Results of Ferric Citrate for Iron Deficiency Anemia (IDA) in Non-Dialysis Dependent Chronic Kidney Disease (NDD-CKD)
- Keryx Biopharmaceuticals Announces U.S. FDA Approval of Second Contract Manufacturer for Auryxia® (ferric citrate)
- Keryx Biopharmaceuticals Announces Third Quarter 2016 Financial Results and Provides Corporate Update
- Keryx Biopharmaceuticals to Webcast its Presentation at Stifel’s 2016 Healthcare Conference on November 15
- Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2016 Financial Results on Wednesday, November 9, 2016
- Keryx Biopharmaceuticals Announces Presentations of Data at the American Society of Nephrology Kidney Week 2016 Annual Meeting
- UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders of Keryx Biopharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 3, 2016 - KERX
- KERX INVESTOR ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Keryx Biopharmaceuticals, Inc. and a Lead Plaintiff Deadline of October 3, 2016
- INVESTOR ALERT: Rosen Law Firm Reminds Keryx Biopharmaceuticals Inc. Investors of Important October 3 Deadline in Class Action - KERX
- Robbins Geller Rudman & Dowd LLP Updates Investors Regarding Securities Class Action Suit Against Keryx Biopharmaceuticals, Inc. And Lead Plaintiff Opportunity
- Lifshitz & Miller Law Firm Announces Investigation of BBX Capital Corporation, Concordia International Corp., Corrections Corporation of America, Epiq Systems, Inc., Goldcorp Inc., Keryx Biopharmaceuticals, Inc., Northern Oil and Gas, Inc., and Post Properties, Inc.
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Keryx Biopharmaceuticals Inc. - KERX
- SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Keryx Biopharmaceuticals Inc. (KERX)
- Keryx Biopharmaceuticals Inc. Investigated For Securities Fraud By Block & Leviton After Keryx Halts The Distribution Of Auryxia And Withdraws Its Full-Year Financial Forecast
